<DOC>
	<DOCNO>NCT03069534</DOCNO>
	<brief_summary>Multidrug-resistant tuberculosis ( MDR-TB ) emerge challenge worldwide . Few study prospectively report outcomes patient pulmonary MDR-TB treat adjunctive immunotherapy combine standard chemotherapy . We aim assess whether immunotherapy Interleukin ( IL ) -2 enhance clinical immune effect treatment MDR-TB patients.We perform multicentre prospective cohort study extend Jiangsu province China . Two group generate base adjunctive rhIL-2 therapy 24 month regiman . Bacteriological imaging data follow 24 month cure rate analyse .</brief_summary>
	<brief_title>Study Adjunctive Recombinant Human Interleukin-2 Therapy Patients With MDR-TB</brief_title>
	<detailed_description>IL-2 therapy regimans expect restore immune response change immunologic status , thus allow host efficiently contain eradicate immune response , primarily cancer infectious diseases.To address , perform prospective randomize control multicenter cohort study 8-month adjunctive immunotherapy rhIL-2 MDR-TB patient compare standard chemotherapy . This multicenter prospective clinical study conduct 13 tuberculosis center ( coordinate hospital specialize tuberculosis ) across Jiangsu province , China . Joined network system The First Affiliated Hospital Nanjing Medical University CDC Jiangsu province , participant enrol 2009 2018 . This study protocol approve ethic committee First Affiliated Hospital Nanjing Medical University perform adhere ethical principle Declaration Helsinki . All patient provide write informed consent enrollment . The independent data safety study monitor hospital monitoring committee . Patients enrollment Eligible MDR-TB participant identify triplicate-spot sputum smear positive acid-fast bacillus positive sputum culture resistance isoniazid rifampin , determine susceptibility test rapid screen test . The result assay confirm use L-G medium base modify Jiangsu province Centers Disease Control Prevention（CDC） . Treatment plan two cohort : The patient rhIL-2 group give consist four course low-dose rhIL-2 ( 500，000 U/m ) give subcutaneously ( SC ) every day ( q.o.d . ) 30 day . Four course carry separately month 1 , 3 , 5 , 7 . All enrol patient pulmonary MDR-TB receive 24-month standard anti-MDR-TB chemotherapy regimen:6-month Z+KM/AM CM + PAS/ ( Pa ) + PTO +LFX intensive phase treatment , follow 18-month Z + LFX + PTO + PAS/ ( Pa ) consolidation phase treatment . ( Z : Pyrazinamide ; KM : Kanamycin ; AM : Amikacin ; CM : Capreomycin ; LFX : Levofloxacin ; PTO : Prothionamide ; PAS : Para-aminosalicylicacid ; Pa : Pasiniazid ) ; After finish treatment regimen patient follow minimum 36- month discontinuation regimen , withdrawal consent , loss follow-up , death , end study . For participant demographic measurement record first clinical visit . Patient data collect enrollment quarterly interval . Sputum smear conversion , sputum culture conversion chest CT scan improvement follow 3 , 6 , 12 , 18 , 24 month bacteriological image data collect . Cure rate analyse compare group . The proportion MDR-TB patient two group achieve sputum smear/culture conversion , lung lesion absorption assess compare . Safety assessment include clinical symptom observation , Incidences adverse event （AE ）in two group assess compare . blood routine test , hematologic profile , blood biochemical examination include hepatic aminotransferase blood ureantrogen/creatinine , blood electrolyte test ( potassium , magnesium , calcium ) , serum thyroid stimulate hormone ( TSH ) , audiology examination , visual field color examination . Cure rate define first outcome . Sputum conversion rate define second outcome .</detailed_description>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Antitubercular Agents</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>Patients had/were : 1. confirm case MDRTB ; 2. aged 1870 year old ; 3. chest CT show visible lung lesion , without hole ; 4. fast plasma glucose le 7.8 mol/L normal fundus examination , diabetic ; 5. voluntarily join study sign informed consent form . 1. two total allergy drug food allergy ; 2. resistant drug program ; 3. severe disorder liver , kidney , hematologic system function ; 4. metabolic disease , autoimmune disease , endocrine disease , cancer , HIV/AIDS ; 5. longterm use immunosuppressive agent ; 6. blood system dysfunction ; 7. history mental illness epilepsy ; 8. pregnant lactating ; 9. participate another clinical trial last 3 month currently participate ongoing clinical trial ; 10. longterm alcohol abuse &gt; 10 year two alcoholic drink per day ) ; 11. factor render unsuitable participate project , history unreliability .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>MDR-TB</keyword>
	<keyword>rhIL-2</keyword>
	<keyword>immunotherapy</keyword>
</DOC>